Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Peres

Showing results (181-190 of 208) with videos related to

Pageof 21
Sort By:
Frontiers in Immunology|January 5, 2026
Chronic stress drives ovarian cancer progression via myeloid-derived suppressor cells infiltration and Notch signaling pathway activationYadiel A Rivera-López, Alanis P Torres-Rosado, Jaydiel A Casiano-Martínez, et al.
Frontiers in Cellular and Infection Microbiology|May 13, 2022
<i>Pseudomonas aeruginosa</i> Infection Modulates the Immune Response and Increases Mice Resistance to <i>Cryptococcus gattii</i>Eluzia C Peres-Emidio, Gustavo J C Freitas, Marliete C Costa, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 4, 2022
Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian CarcinomaLauren C Peres, Christelle Colin-Leitzinger, Sweta Sinha, et al.
Cancer Research|August 30, 2019
High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort ConsortiumLauren C Peres, Adrianne R Mallen, Mary K Townsend, et al.
Blood Cancer Journal|April 14, 2025
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myelomaStefanie Palfi, Lauren C Peres, Himara Koelmeyer, et al.
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Blood Advances|June 12, 2023
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myelomaDae Hyun Lee, Abhishek Kumar, Turab Mohammed, et al.
Clinical Epigenetics|July 30, 2025
Retrotransposon methylation profiles and survival in Black women with high-grade serous ovarian carcinomaChristelle Colin-Leitzinger, Katherine A Lawson-Michod, Courtney E Johnson, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Transplantation and Cellular Therapy|June 18, 2026
Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary OutcomesNathan H Parker, Jongphil Kim, Morgan Bean, et al.
Pageof 21

Showing results (181-190 of 208) with videos related to

Sort By:
Pageof 21
Frontiers in Immunology|January 5, 2026
Chronic stress drives ovarian cancer progression via myeloid-derived suppressor cells infiltration and Notch signaling pathway activationYadiel A Rivera-López, Alanis P Torres-Rosado, Jaydiel A Casiano-Martínez, et al.
Frontiers in Cellular and Infection Microbiology|May 13, 2022
<i>Pseudomonas aeruginosa</i> Infection Modulates the Immune Response and Increases Mice Resistance to <i>Cryptococcus gattii</i>Eluzia C Peres-Emidio, Gustavo J C Freitas, Marliete C Costa, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 4, 2022
Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian CarcinomaLauren C Peres, Christelle Colin-Leitzinger, Sweta Sinha, et al.
Cancer Research|August 30, 2019
High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort ConsortiumLauren C Peres, Adrianne R Mallen, Mary K Townsend, et al.
Blood Cancer Journal|April 14, 2025
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myelomaStefanie Palfi, Lauren C Peres, Himara Koelmeyer, et al.
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Blood Advances|June 12, 2023
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myelomaDae Hyun Lee, Abhishek Kumar, Turab Mohammed, et al.
Clinical Epigenetics|July 30, 2025
Retrotransposon methylation profiles and survival in Black women with high-grade serous ovarian carcinomaChristelle Colin-Leitzinger, Katherine A Lawson-Michod, Courtney E Johnson, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Transplantation and Cellular Therapy|June 18, 2026
Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary OutcomesNathan H Parker, Jongphil Kim, Morgan Bean, et al.
Pageof 21